Strong LecTec NatusPatch(R) sales on QVC: New pharmaceutical production line to meet growing retail demand.
The company said QVC sold out its entire NatusPatch inventory during two showings on Feb. 6. Two selling sessions in early January were also sell-outs.
To meet demand from anticipated future QVC showings and additional retail initiatives, the company said it is investing in a new pharmaceutical production line dedicated to patch products. The new line, which will have approximately five times the capacity of the existing line, will commence volume production by early summer.
The company said it expects to manufacture a growing range of patch products, utilizing LecTec's proprietary membrane technology, on the new equipment. The new production line is being supported entirely with internally-generated cash.
The NatusPatch is distributed by Natus Corp., a subsidiary of LecTec.
LecTec develops, manufactures and markets skin-related medical products based on patented hydrogel membrane technology. The company's core businesses include diagnostic electrodes for electrocardiography and medical tapes. The company is focusing an extensive R&D effort on its emerging therapeutic products business. LecTec common stock is traded on the NASDAQ National Market System under the symbol LECT.
CONTACT: LecTec Corp., Minnetonka
Erwin W. Templin II, 612/933-2291 or fax: 612/933-4808
|Printer friendly Cite/link Email Feedback|
|Date:||Feb 9, 1995|
|Previous Article:||Cambior announces its 1994 production results.|
|Next Article:||New Air France summer schedule brings more of Europe to Houston.|